PDCD1 and non-small cell lung carcinoma: In conclusion, our results highlight the important role of high-dose AA in the anticancer efficacy of anti-PD1 in lung cancer models and suggest that high-dose AA may be a potential adjuvant for improving the efficacy of anti-PD1 immunotherapy in NSCLC.